The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection

Gastrointestinal Endoscopy

Volumn 87, Issue 1, 2018, Pages 18-29

  Allegretti, Jessica R ^a,b   Kassam, Zain ^c   Osman, Majdi ^b,c,d   Budree, Shrish ^c,e   Fischer, Monika ^f   Kelly, Colleen R ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Open Biome   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f INDIANA UNIVERSITY   (United States)

^g BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA;

BILE ACID METABOLISM; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; DISEASE TRANSMISSION; DONOR; DONOR SELECTION; ENDOSCOPY; FECAL MICROBIOTA TRANSPLANTATION; FECES; FECES ANALYSIS; FOLLOW UP; HOSPITAL DISCHARGE; INTESTINE PREPARATION; MICROBIAL COMMUNITY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAFETY; SCREENING; SIGMOIDOSCOPY; DIRECTIVE COUNSELING; HUMAN; PATIENT PARTICIPATION; PATIENT SELECTION; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; PSEUDOMEMBRANOUS COLITIS; TREATMENT CONTRAINDICATION;

CLOSTRIDIUM DIFFICILE; CONTRAINDICATIONS, PROCEDURE; DIRECTIVE COUNSELING; DONOR SELECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; PATIENT DISCHARGE; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; PATIENT SELECTION;

EID: 85025101641     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2017.05.036     Document Type: Review

References (79)

1. Lessa, F.C., Winston, L.G., McDonald, L.C., Emerging Infections Program C. difficile Surveillance Team. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 2369–2370.
2. Lessa, F.C., Mu, Y., Bamberg, W.M., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 825–834.
3. Shaughnessy, M.K., Amundson, W.H., Kuskowski, M.A., et al. Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection. Infect Control Hosp Epidemiol 34 (2013), 109–116.
4. Gould, C.V., Edwards, J.R., Cohen, J., et al. Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis 57 (2013), 1304–1307.
5. Longtin, Y., Trottier, S., Brochu, G., et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 56 (2013), 67–73.
6. Persson, S., Jensen, J.N., Olsen, K.E., Multiplex PCR method for detection of Clostridium difficile tcdA, tcdB, cdtA, and cdtB and internal in-frame deletion of tcdC. J Clin Microbiol 49 (2011), 4299–4300.
7. Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol, 108, 2013, 478 98; quiz 499.
8. Surawicz, C.M., McFarland, L.V., Greenberg, R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 (2000), 1012–1017.
9. Gerding, D.N., Metronidazole for Clostridium difficile–associated disease: Is it okay for mom?. Clin Infect Dis 40 (2005), 1598–1600.
10. Wenisch, C., Parschalk, B., Hasenhundl, M., et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile–associated diarrhea. Clin Infect Dis 22 (1996), 813–818.
11. Sadowsky, M.J., Khoruts, A., Faecal microbiota transplantation is promising but not a panacea. Nat Microbiol, 1, 2016, 16015.
12. Weingarden, A.R., Chen, C., Bobr, A., et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306 (2014), G310–G319.
13. Mullish B, McDonald J, Kao D, et al. Understanding the mechanisms of efficacy of fecal microbiota transplantation in the treatment of Clostridium difficile infection: the potential role of bile-metabolising enzymes. Gastroenterology 2017;152(Suppl 1):S47.
14. Allegretti, J.R., Kearney, S., Li, N., et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther 43 (2016), 1142–1153.
15. Khoruts, A., Sadowsky, M.J., Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 13 (2016), 508–516.
16. Cammarota, G., Ianiro, G., Gasbarrini, A., Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 48 (2014), 693–702.
17. Kelly, C.R., Khoruts, A., Staley, C., et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 165 (2016), 609–616.
18. van Nood, E., Vrieze, A., Nieuwdorp, M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (2013), 407–415.
19. Youngster, I., Sauk, J., Pindar, C., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 58 (2014), 1515–1522.
20. Kassam, Z., Lee, C.H., Hunt, R.H., Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin Lab Med 34 (2014), 787–798.
21. Drekonja, D., Reich, J., Gezahegn, S., et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 162 (2015), 630–638.
22. Kassam, Z., Lee, C.H., Yuan, Y., et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 108 (2013), 500–508.
23. Wang, S., Xu, M., Wang, W., et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One, 11, 2016, e0161174.
24. Smith, M.B., Kelly, C., Alm, E.J., Policy: how to regulate faecal transplants. Nature 506 (2014), 290–291.
25. U.S. Food and Drug Administration. Guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Available at: https://Www.fda.gov/downloads/biologicsblood vaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/UCM488223.pdf. Accessed May 2017.
26. Kelly, C.R., Kunde, S.S., Khoruts, A., Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol Hepatol 12 (2014), 283–288.
27. Lieberman A, Munoz R, Edelstein C, et al. The impact of stool banks on access to fecal microbiota transplantation for recurrent Clostridium difficile infection in the United States: a geospatial analysis. Poster presented at: American College of Gastroenterology Meeting; October 14-19, 2016; Las Vegas, NV.
28. Kelly, C.R., Kahn, S., Kashyap, P., et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149 (2015), 223–237.
29. Bakken, J.S., Borody, T., Brandt, L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9 (2011), 1044–1049.
30. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. Epub 2017 Jan 13.
31. Fischer, M., Sipe, B.W., Rogers, N.A., et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 42 (2015), 470–476.
32. Aroniadis, O.C., Brandt, L.J., Greenberg, A., et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 50 (2016), 398–402.
33. Fischer, M., Rex, D.K., Sipe, B.W., Letter: Faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection—authors’ reply. Aliment Pharmacol Ther, 42, 2015, 1031.
34. Fischer M, Sipe B, Cheng YW, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes. Epub 2016 Dec 21.
35. Crobach, M.J., Planche, T., Eckert, C., et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 22:suppl 4 (2016), S63–S81.
36. Jackson, M., Olefson, S., Machan, J.T., et al. A high rate of alternative diagnoses in patients referred for presumed Clostridium difficile infection. J Clin Gastroenterol 50 (2016), 742–746.
37. Saeedi, B.J., Morison, D.G., Kraft, C.S., et al. Fecal microbiota transplant for Clostridium difficile infection in a pregnant patient. Obstet Gynecol 129 (2017), 507–509.
38. Kelly, C.R., Ihunnah, C., Fischer, M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109 (2014), 1065–1071.
39. Infectious Disease Society of America. Available at: https://www.gastro.org/research/Joint_Society_FMT_Guidance.pdf. Accessed May, 2017.
40. Edelstein, C., Daw, J.R., Kassam, Z., Seeking safe stool: Canada needs a universal donor model. CMAJ 188 (2016), E431–E432.
41. Bakken, J.S., Polgreen, P.M., Beekmann, S.E., et al. Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe 24 (2013), 20–24.
42. Hamilton, M.J., Weingarden, A.R., Sadowsky, M.J., et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (2012), 761–767.
43. Lee, C.H., Steiner, T., Petrof, E.O., et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 315 (2016), 142–149.
44. Smith, M., Kassam, Z., Edelstein, C., et al. OpenBiome remains open to serve the medical community. Nat Biotechnol, 32, 2014, 867.
45. Smith, M., Kassam, Z., Burgess, J., et al. The international public stool bank: a scalable model for standardized screening and processing of donor stool for fecal microbiota transplantation. Gastroenterology, 148, 2015 S-211.
46. Dubois, N., Ling, K., Osman, M., et al. Prospective assessment of donor eligibility for fecal microbiota transplantation at a public stool bank: Results from the evaluation of 1387 candidate donors. Open Forum Infect Dis, 2(suppl 1), 2016, 962.
47. Osman, M., O'Brien, K., Stoltzner, Z., et al. Safety and efficacy of fecal microbiota transplantation for recurrent Clostridium difficile infection from an international public stool bank: results from a 2050-patient multicenter cohort. Open Forum Infect Dis, 3(suppl 1), 2016, S599.
48. Bate, S.L., Dollard, S.C., Cannon, M.J., Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 50 (2010), 1439–1447.
49. Rossen, N.G., Fuentes, S., van der Spek, M.J., et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149 (2015), 110–118.e4.
50. Hohmann, E.L., Ananthakrishnan, A.N., Deshpande, V., Case records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N Engl J Med 371 (2014), 668–675.
51. Baxter, M., Colville, A., Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect 92 (2016), 117–127.
52. Quera, R., Espinoza, R., Estay, C., et al. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. J Crohns Colitis 8 (2014), 252–253.
53. Aas, J., Gessert, C.E., Bakken, J.S., Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36 (2003), 580–585.
54. De Leon, L.M., Watson, J.B., Kelly, C.R., Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 11 (2013), 1036–1038.
55. Kunde, S., Pham, A., Bonczyk, S., et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 56 (2013), 597–601.
56. Mandalia, A., Kraft, C.S., Dhere, T., Diverticulitis after fecal microbiota transplant for C. difficile infection. Am J Gastroenterol 109 (2014), 1956–1957.
57. van Nood, E., Speelman, P., Kuijper, E.J., et al. Struggling with recurrent Clostridium difficile infections: Is donor faeces the solution?. Euro Surveill, 14, 2009, 19316.
58. Brandt, L.J., Aroniadis, O.C., Mellow, M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (2012), 1079–1087.
59. Newman, K.M., Rank, K.M., Vaughn, B.P., et al. Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes 8 (2017), 303–309.
60. Khoruts, A., Rank, K.M., Newman, K.M., et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 14 (2016), 1433–1438.
61. Moayyedi, P., Surette, M.G., Kim, P.T., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149 (2015), 102–109.e6.
62. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. Epub 2017 Feb 14.
63. Fischer, M., Kao, D., Mehta, S.R., et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol 111 (2016), 1024–1031.
64. Obi, O., Hampton, D., Anderson, T., et al. Fecal microbiota transplant for treatment of resistant C. difficile infection using a standardized protocol: a community hospital experience. Am J Gastroenterol, 109(suppl 2), 2014, S629.
65. Baxter, M., Ahmad, T., Colville, A., et al. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis 61 (2015), 136–137.
66. Environmental Protection Agency. Available at: https://www.epa.gov/sites/production/files/2017-01/documents/20172701.listk_.pdf.
67. Zipursky, J.S., Sidorsky, T.I., Freedman, C.A., et al. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 55 (2012), 1652–1658.
68. Lee, C.H., Belanger, J.E., Kassam, Z., et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis 33 (2014), 1425–1428.
69. Varier, R.U., Biltaji, E., Smith, K.J., et al. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clin Microbiol Infect 20 (2014), 1343–1351.
70. Varier, R.U., Biltaji, E., Smith, K.J., et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 36 (2015), 438–444.
71. van Beurden, Y.H., van Gils, T., van Gils, N.A., et al. Serendipity in refractory celiac disease: full recovery of duodenal villi and clinical symptoms after fecal microbiota transfer. J Gastrointest Liver Dis 25 (2016), 385–388.
72. Youngster, I., Russell, G.H., Pindar, C., et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312 (2014), 1772–1778.
73. Youngster, I., Mahabamunuge, J., Systrom, H.K., et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med, 14, 2016 134,016-0680-9.
74. Hirsch, B.E., Saraiya, N., Poeth, K., et al. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis, 15, 2015 191,015-0930-z.
75. Allegretti J, Fischer M, Papa E, et al. Fecal microbiota transplantation delivered via oral capsules achieves microbial engraftment similar to traditional delivery modalities: safety, efficacy and engraftment results from a multi-center cluster randomized dose-finding study. Gastroenterology 2016;150(Suppl 1):S540.
76. Jalanka, J., Salonen, A., Salojarvi, J., et al. Effects of bowel cleansing on the intestinal microbiota. Gut 64 (2015), 1562–1568.
77. O'Brien, C.L., Allison, G.E., Grimpen, F., et al. Impact of colonoscopy bowel preparation on intestinal microbiota. PLoS One, 8, 2013, e62815.
78. Fischer M, Phelps E, Bolla R, et al. Long term risk of Clostridium difficile infection recurrence with or without antibiotics exposure following successful fecal microbiota transplant. Presented at Digestive Disease Week; May 21-24, 2016; San Diego, CA.
79. Wadhwa, A., Al Nahhas, M.F., Dierkhising, R.A., et al. High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection. Aliment Pharmacol Ther 44 (2016), 576–582.